Related Experiment Video

Updated: May 21, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review)

Hiroshi Shigetomi1, Yumi Higashiura, Hirotaka Kajihara

  • 1Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8522, Japan.

Oncology Reports
|May 30, 2012
PubMed

Insights

New targeted therapies, including angiogenesis and poly (ADP ribose) polymerase (PARP) inhibitors, show promise for specific epithelial ovarian cancer patient groups. These treatments aim to improve current therapeutic strategies by targeting DNA repair mechanisms.

Area of Science:

  • Oncology
  • Genetics

Background:

  • Epithelial ovarian cancer (EOC) treatment strategies are evolving with advances in gene expression profiling and targeted therapies.
  • Novel therapeutic agents are being developed to improve patient outcomes.

Purpose of the Study:

  • To review ongoing and planned clinical trials for EOC.
  • To provide a synopsis of preclinical and clinical targeted therapies for EOC.

Main Methods:

  • Literature review of English-language publications.
  • Focus on ongoing and planned clinical trials.
  • Analysis of targeted agents including angiogenesis inhibitors, poly (ADP ribose) polymerase (PARP) inhibitors, and DNA repair mechanism inhibitors.

Main Results:

  • Targeted therapies, such as PARP or homologous recombination (HR) repair inhibitors, show potential for specific patient populations.
  • Inhibition of PARP or HR repair can sensitize specific tumor cells (e.g., BRCAness phenotype, HNF-1β-overexpressing cells) to chemotherapy.
  • Therapeutic response is likely to be patient-specific rather than broadly applicable.

Conclusions:

  • Targeted therapies offer a promising avenue for improving EOC treatment effectiveness in select patient groups.
  • Challenges remain in identifying responsive populations and optimizing treatment strategies.
  • Further research into personalized medicine approaches is warranted for EOC.

More Related Videos

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...